150 mg Blister
Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68084-698
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68084-698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
150 mg Carton
This is a pharmaceutical product, specifically Venlafaxine Hydrochloride Extended-Release Capsules USP. Each capsule contains 150mg of venlafaxine hydrochloride USP. The usual dosage is provided in the package insert. The drug should be stored between 20-25°C (66-77°F) with excursions permitted between 15-30°C (59-86°F). It is distributed by American Health Packaging and comes in a 100 capsule bottle. The accompanying medication guide should be dispensed with each bottle, and the product should be kept away from children. The product should not be used if the blister pack is damaged.*
37.5 mg Blister
37.5 mg Carton
This is a medication package for Venlafaxine Hydrochloride Extended-Release Capsules USP, containing 100 capsules (10x10) with each capsule having 375mg of Venlafaxine. The usual prescription dosage direction is indicated on the package insert. The package should be kept between 20°C to 25°C (68°F to 77°F), but excursions up to 30°C (86°F) are permitted. The medication should be kept away from the reach of children and should not be used if the package is damaged. The drug is from Aurobindo Pharma USA, Inc., and the package is distributed by American Health Packaging located in Columbus, Ohio.*
75 mg Blister
75 mg Carton
Ahp69801
Ahp70901
Ahp71301
Figure 1
This is a description of a drug interaction with cimetane and the analyte Aniatxine, Vov, Veniatxine and Venistaxing. The recommendation is to use caution when using the drugs together as there may be an increase in PK Fold Change and 90% CI. It suggests monitoring blood pressure in patients who are at risk for hypertension, liver dysfunction, and geriatric patients. It also mentions that the clinical significance is unknown and that a dose adjustment may be necessary. There is no mention of a change relative to the reference value.*
Figure 2
Figure 3
Structure
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
